Alerts will be sent to your verified email
Verify EmailTATVA
|
Tatva Chintan Pharma
|
Camlin Fine Sciences
|
Styrenix Performance
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Chemicals
|
|||
|
Capacity Utilization - Chemicals - Reactor
|
64.11 % | n/a | n/a |
|
Pharmaceuticals
|
|||
|
Total reactor capacity
|
552.0 kL | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
13.1 % | -0.75 % | 16.0 % |
|
5yr average Equity Multiplier
|
1.4 | 2.29 | 2.03 |
|
5yr Average Asset Turnover Ratio
|
0.62 | 0.81 | 1.67 |
|
5yr Avg Net Profit Margin
|
11.89 % | -0.61 % | 5.53 % |
|
Price to Book
|
3.62 | 3.03 | 2.68 |
|
P/E
|
83.39 | 0.0 | 16.63 |
|
5yr Avg Cash Conversion Cycle
|
137.87 Days | 30.19 Days | 38.35 Days |
|
Inventory Days
|
121.92 Days | 107.15 Days | 45.15 Days |
|
Days Receivable
|
72.59 Days | 67.17 Days | 44.64 Days |
|
Days Payable
|
79.07 Days | 122.28 Days | 61.71 Days |
|
5yr Average Interest Coverage Ratio
|
11.05 | 2.4 | 39.17 |
|
5yr Avg ROCE
|
15.09 % | 13.22 % | 18.95 % |
|
5yr Avg Operating Profit Margin
|
17.59 % | 12.42 % | 9.29 % |
|
5 yr average Debt to Equity
|
0.24 | 0.82 | 0.18 |
|
5yr CAGR Net Profit
|
-35.78 % | n/a | 65.52 % |
|
5yr Average Return on Assets
|
8.28 % | -0.48 % | 9.47 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.02 % | 48.03 % | 46.24 % |
|
Share Pledged by Promoters
|
0.0 | 10.84 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-7.15 % | 30.39 % | -16.49 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-7.87 % | -4.6 % | 8.21 % |
|
Tatva Chintan Pharma
|
Camlin Fine Sciences
|
Styrenix Performance
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|